USANA Health Sciences Inc - מכפיל P/S עתידי USNA
High competition in the dietary supplement segment hinders expansion, creating risks for USANA Health Sciences (USNA). However, the phenomenal scale of its distributor network and proprietary manufacturing plants in the US and China ensure stability. The forward price-to-sales ratio demonstrates a support level where the parameter value equals 0.30, confirming the market's current valuation relative to the issuer's expected revenues.
USNA (USANA Health Sciences): פילוחים אנליטיים ודוחות לפי אינדיקטורים
USANA Health Sciences (USNA) ensures revenue stability and eliminates logistical disruptions through its own manufacturing facilities and raw material diversification. This operational resilience directly impacts the forward P/S ratio, which compares current market capitalization to expected future sales volumes. The multiple measures the market value of one dollar of projected revenue, revealing long-term business valuation trends. Analyzing the forward P/S valuation of USANA Health Sciences (USNA) allows investors to distinguish fundamental asset undervaluation from a systemic loss of market share.
